US SB250 | 2021-2022 | 117th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on February 4 2021 - 25% progression, died in committee
Action: 2021-02-04 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 4 2021 - 25% progression, died in committee
Action: 2021-02-04 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs, and for other purposes.
Title
Fairness in Orphan Drug Exclusivity Act
Sponsors
| Sen. Bill Cassidy [R-LA] | Sen. Tammy Baldwin [D-WI] | Sen. Jeanne Shaheen [D-NH] |
History
| Date | Chamber | Action |
|---|---|---|
| 2021-02-04 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB1629 (Related) 2021-05-20 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
HR403 (Similar To) 2021-05-18 - Motion to reconsider laid on the table Agreed to without objection.
HR403 (Similar To) 2021-05-18 - Motion to reconsider laid on the table Agreed to without objection.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/117th-congress/senate-bill/250/all-info |
| Text | https://www.congress.gov/117/bills/s250/BILLS-117s250is.pdf |
